NewsBenzingaZenaTech Targets 2027 Adjusted EBITDA Breakeven On Revenue Growth, Expanding Drone As A Service Operations; Preliminary Q3 2026 Revenue Of C$13.4–C$14.8 Million ZenaTech Targets 2027 Adjusted EBITDA Breakeven On Revenue Growth, Expanding Drone As A Service Operations; Preliminary Q3 2026 Revenue Of C$13.4–C$14.8 Million Benzinga 2026.10.26 13:18 (GMT+0) Open on Benzinga Other news Why Is Pinterest Stock Falling on Monday? TD Cowen Maintains Buy on Live Oak Bancshares, Lowers Price Target to $41 Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer TD Cowen Maintains Hold on Infosys, Raises Price Target to $11 GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma TD Cowen Maintains Buy on Flagstar Bank, Lowers Price Target to $13
Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer
GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma
